Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection
Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment
Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection
Sponsors
Fifth People's Hospital of Ganzhou
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged >=18 years; (2) Novel coronavirus pneumonia patients diagnosed by pathogenic testing; (3) The patient himself participated in the study voluntarily, agreed and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Meet the diagnostic criteria for severe new-type coronavirus infection pneumonia; (2) Severe primary diseases that affect survival, including: uncontrolled malignant tumors, hematological diseases, and HIV that have not been metastasized in multiple places; (3) Obstructive pneumonia, pulmonary interstitial fibrosis, alveolar proteinosis, and allergic alveolitis caused by lung tumors; (4) Women who are breastfeeding or pregnant; (5) Those who are known to be allergic to the ingredients contained in the research medication, or patients with allergies; (6) Those who have continued to use immunosuppressive agents or organ transplants in the past 6 months; (7) Patients who have participated in other drug clinical trials within 3 months before the screening test; (8) The investigator judges that he or she cannot complete or should not participate in the study (expected death within 48 hours, and the patient refuses active treatment)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical recovery time;Pneumonia Severity Index (PSI) score; | — |
Countries
China
Contacts
Public ContactXie Liangdong
Fifth People's Hospital of Ganzhou
Outcome results
None listed